Evotec SE — Regulatory Filings 2003

Apr 10, 2003

News Details

Corporate | 10 April 2003 09:26

Evotec OAI AG english

Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Hamburg, Germany | Abingdon, UK – Evotec OAI (Deutsche Börse: EVT, Prime Standard), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, today announced that it has signed an assay development and screening contract to identify drug candidates for several undisclosed Novartis targets. Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: “Following a successful collaboration in the development of our EVOscreen uHTS system, Novartis has chosen Evotec OAI to support their lead discovery efforts. We are delighted that one of the world’s leading R&D organisations has chosen our expertise in drug discovery and our technology platform in this critical area of research.” In early 1996 Novartis decided to invest in the development of Evotec OAI’s EVOscreen uHTS technology, becoming the first technology development collaborator. Evotec OAI provides the full spectrum of services to take clients’ projects from target to IND. Fast assay development and highly sensitive high-throughput screening services are part of its integrated offering. Applying innovative and validated proprietary technologies, more than 120 novel biological assays have been developed from a wide variety of target classes, including kinases, phosphatases, proteases, GPCRs, ion channels, DNA-binding proteins and protein/protein interactions. In 2002 the Company greatly increased its capabilities in performing cellular assays including reporter assays, protein translocation and cytotoxicity assays at the medium throughput and uHTS level. About Evotec OAI AG Evotec OAI has established itself as the partner of choice for drug discovery and development services for the world’s premier pharmaceutical and biotechnology companies, maintaining its leadership role through innovation and unmatched customer service. Our business strategy is clearly focussed on drug discovery. We have established the most comprehensive technology platform and skills that integrate our world- class biology and chemistry capabilities. We leverage this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, we engage in selected discovery programmes ourselves to develop drug candidates for early outlicensing. Our instrument and technology business is now successfully handled by our affiliate, Evotec Technologies. With over 600 people in Hamburg, Germany and Abingdon, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities. Contact: Anne Hennecke, Investor Relations & Corporate Communications, Evotec OAI AG, Phone: +49/40/56081-286, anne.hennecke@evotecoai.com end of message, (c)DGAP 10.04.2003 ——————————————————————————– WKN: 566480; ISIN: DE0005664809; Index: TecDAX, NEMAX 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 100926 Apr 03